Filing Flows › UroGen Pharma (URGN) › Jelmyto revenue
UroGen Pharma (URGN) Jelmyto revenue by quarter
UroGen Pharma's Jelmyto revenue was $21.0M in Q3 2026 (third quarter 2026), -5% from Q2 2026. Over the last 5 quarters it ranged from $21.0M (Q3 2026) to $25.7M (Q3 2025).
| Quarter | Jelmyto revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $21.0M | -5% | -18% |
| Q2 2026 | $22.0M | +1% | — |
| Q1 2026 | $21.7M | -9% | — |
| Q4 2025 | $23.8M | -7% | — |
| Q3 2025 | $25.7M | — | — |
Q3 2026 at a glance
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is UroGen Pharma's Jelmyto revenue?
UroGen Pharma's Jelmyto revenue was $21.0M in Q3 2026 (third quarter 2026), -5% from Q2 2026.
How has UroGen Pharma's Jelmyto revenue changed?
Over the last 5 quarters it ranged from $21.0M (Q3 2026) to $25.7M (Q3 2025).